Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPG blocks for migraine prevention
NCT03666663Phase 4Completed
- Sponsor
- University of California, San Francisco
- Start
- Feb 2019
- Primary completion
- Jul 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of lidocaine 10% oropharyngeal spray, bupivacaine and ropivacaine in migraine (4 arms), sponsored by University of California, San Francisco. Primary endpoint: Number of Participants With a Reduction in Headache Days From Baseline to Month 8 of Treatment. Started Feb 2019; status: completed.
02
Drugs
lidocaine 10% oropharyngeal spraybupivacaineropivacaine
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03666663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03666663.